Successful genotype-tailored treatment with small-dose efavirenz

AIDS

Volumn 23, Issue 3, 2009, Pages 433-434

  Gatanaga, Hiroyuki ^a   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 2B6; EFAVIRENZ;

CENTRAL NERVOUS SYSTEM DISEASE; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG METABOLISM; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; NIGHTMARE; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

AGED; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACOGENETICS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 59849124607     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32831940e3     Document Type: Letter

References (4)

1. King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008; 22:1709-1717.
2. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, et al. Successful efavirenzdose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45:1230-1237.
3. Hasse B, Gunthard HF, Bleiber G, Krause M. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 2005; 40:e22-e23.
4. Mein CA, Barratt BJ, Dunn MG, Siegmund T, Smith AN, Esposito L, et al. Evaluation of single nucleotide polymorphism typing with invader on PCR amplicon and its automation. Genome Res 2002; 10:330-343.